Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.
100 Clinical Results associated with Avana Health, Inc.
0 Patents (Medical) associated with Avana Health, Inc.
100 Deals associated with Avana Health, Inc.
100 Translational Medicine associated with Avana Health, Inc.